Current Report Filing (8-k)
December 22 2016 - 5:21PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported)
December 22,
2016
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
Nevada
|
000-52138
|
20-2000871
|
(State or other jurisdiction of
|
(Commission File Number)
|
(IRS Employer
|
incorporation)
|
|
Identification No.)
|
156 Valleyview Road, Kelowna, BC Canada
|
V1X 3M4
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrants telephone number, including area code
(250)
765-6424
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR
240.14a-12)|
[ ] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement
On December 22, 2016, Lexaria Bioscience Corp. (Lexaria)
announced that it has extended the services of Frontier Merchant Capital Group
(Frontier) with a head office in Toronto, Canada, for a period of three
months. Lexaria will pay CDN $25,000 + GST. The initial engagement of Frontiers
services was previously announced in Lexarias news release dated June 6, 2016.
Frontier will assist Lexaria by increasing market awareness
utilizing a number of financial market communication initiatives including media
outreach, facilitating in-person introduction for Lexaria with institutional and
retail brokers and investors in cities across Canada and the US, and more.
Item 7.01 Regulation FD Disclosure
A copy of the news release announcing that Lexaria has extended
the services of Frontier Merchant Capital Group is filed as exhibit 99.1 to this
current report and is hereby incorporated by reference.
- 2 -
Item 9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
/s/ Chris Bunka
Chris Bunka
CEO,
Principal Executive Officer
Date: December 22, 2016